





Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer

Guilherme Harada¹, Maria Fernanda Batistuzzo Vicentini Neffa¹,
 Renata Colombo Bonadio¹, Elizabeth Zambrano Mendoza¹,
 Rafael Caparica², Letícia Leone Lauricella¹, Teresa Yae Takagaki¹,
 Felipe Santa Rosa Roitberg¹, Ricardo Mingarini Terra¹, Gilberto De Castro Jr¹




Number at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96
No adjuvant CT	41	24	21	18	14	7	4	3	3	1	0	0	0	0	0	0	0
Adjuvant CT	33	28	24	20	16	13	12	12	12	8	7	5	2	2	1	0	0



Number at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96
No adjuvant CT	41	28	22	22	19	11	9	7	5	2	1	1	0	0	0	0	0
Adjuvant CT	33	29	27	24	19	15	14	12	12	8	7	5	2	2	1	0	0


Figure S1. Recurrence-free survival (A) and overall survival (B) curves in patients with stage II non-small cell lung cancer, comparing those treated with cisplatin + vinorelbine with those not treated with adjuvant chemotherapy (controls). HR: hazard ratio; and CT: chemotherapy.

(A)



Number at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96
No adjuvant CT	23	11	6	4	3	3	2	2	2	1	1	1	1	1	1	1	1
Adjuvant CT	20	18	14	8	7	7	7	5	5	4	2	2	2	2	1	0	0

(B)



Number at risk	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96
No adjuvant CT	23	13	12	7	5	4	3	3	3	3	2	2	2	1	1	1	1
Adjuvant CT	20	18	15	11	10	10	7	5	5	4	3	2	2	2	1	0	0

Figure S2. Recurrence-free survival (A) and overall survival (B) curves in patients with stage III non-small cell lung cancer, comparing those treated with cisplatin + vinorelbine with those not treated with adjuvant chemotherapy (controls). HR: hazard ratio; and CT: chemotherapy.